Providers
Integrated Insights from a Single Sample
More comprehensive than FISH, from a routine blood draw or bone marrow – providing deeper genomic insight to support your treatment decisions.
Jump Down:
Integrated Insights
Introducing GenoPredicta
Genopredicta is the first blood-based molecular intelligence platform that delivers a comprehensive genomic view of multiple myeloma, enabling precision treatment selection and disease monitoring from a single blood draw.
Clinical validation demonstrated >95% concordance with bone marrow–based genomic testing while identifying actionable mutations not detected by standard FISH analysis.
Limits of standard testing
The Diagnostic Gap
in Multiple Myeloma
Standard FISH testing remains widely used in hematological malignancy care – but the therapies now available to your patients demand a more complete view of disease than FISH was built to provide.
- FISH cannot detect single nucleotide variants (SNVs) or small insertions and deletions (InDels) – including mutations in TP53, KRAS, NRAS, and other key disease drivers
- FISH does not capture BCMA and GPRC5D mutations that predict resistance to CAR-T and bispecific antibody therapies
- FISH requires high tumor cell content and may miss subclonal variants that drive progression and resistance
- Serial monitoring with repeated bone marrow biopsies is invasive, impractical, and burdensome for patients already undergoing intensive treatment
Insights at every stage
Clinical Utility at Each Stage of Care
Multiple myeloma is a disease that evolves across years of treatment, remission, and relapse. GenoPredicta is designed to be useful at every point in that journey – from first diagnosis through smoldering disease, active treatment, and relapse – including the low disease burden states where serial monitoring is most consequential and most technically demanding.
Risk Stratification
Identify high-risk patients earlier through blood-based molecular profiling.
Therapy Guidance
Support personalized treatment decisions through genomic intelligence.
Longitudinal Monitoring
Track disease evolution through serial blood testing and molecular surveillance.
MRD Assessment
Future Blood-based MRD monitoring to complement marrow assessments.
start Testing
Ordering GenoPredicta
Ordering GenoPredicta is straightforward, and our team supports your institution at every step, from onboarding and specimen collection through result interpretation.
Test Information:
- Accepts standard bone marrow or peripheral blood specimens. No special collection kits required.
- Comprehensive interpretive report designed to support clinical decisions, no specialist consultation needed.
- CLIA-certified Laboratory Developed Test, orderable today.
- Hands-on onboarding and ongoing support throughout testing.
Predicta Newsletter
Enter your email address to subscribe.
Enter Email Address:
Predicta Biosciences
750 Main Street, Lab 413
Cambridge, MA 02139